LPAR1
ENSG00000198121
Target class
GPCR
Chromosome
9
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- LPAR1
- Gene name
- Lysophosphatidic acid receptor 1
- Gene symbol
- LPAR1
- Previous gene symbols
- EDG2
- Protein name
- Lysophosphatidic acid receptor 1 (LPA receptor 1) (LPA-1) (Lysophosphatidic acid receptor Edg-2)
- edg-2
- rec.1.3
- vzg-1
- Gpcr26
- Mrec1.3
- LPA1
- Gene biotype
- Protein coding
- Gene family
- Lysophosphatidic acid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 51
- Highest tissue expression
- 238.85
- Tissue specificity (Gini)
- 0.519
- Tissue specificity (tau)
- 0.832
- KEGG gene identifiers
- hsa:1902
- Protein interaction confidence
- 0.903483
- Protein interaction partners
- 29
- R-HSA-416476
- R-HSA-418594
- R-HSA-419408
- End position
- 111038863
- Start position
- 110871773
- Chromosome
- 9
- Strand
- Reverse
- Cell surface . Cell membrane
- Multi-pass membrane protein . Endosome . Note=Prior to LPA treatment found predominantly at the cell surface. Internalized after LPA treatment. Colocalizes with RALA in endocytic vesicles after LPA treatment. .
- PubMed 19306925
- PubMed 25025571
- PubMed 26091040
- PubMed 9070858
- Tissue specificity (tau)
- 0.832272
- Expression inequality (Gini)
- 0.518986
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 238.85
- Cells - Cultured fibroblasts
- 184.2
- Nerve - Tibial
- 150.85
- Brain - Substantia nigra
- 139.38
- Brain - Hippocampus
- 113.83
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)238.85
- Cells - Cultured fibroblasts184.2
- Nerve - Tibial150.85
- Brain - Substantia nigra139.38
- Brain - Hippocampus113.83
- Brain - Putamen (basal ganglia)112.73
- Brain - Amygdala101.2
- Cervix - Ectocervix92.1
- Artery - Aorta69.13
- Brain - Caudate (basal ganglia)68.13
- Artery - Tibial66.43
- Cervix - Endocervix66.35
- Brain - Hypothalamus61.17
- Vagina49.85
- Adipose - Subcutaneous45.13
- Artery - Coronary43.27
- Bladder43.1
- Brain - Nucleus accumbens (basal ganglia)41.29
- Breast - Mammary Tissue38.48
- Brain - Frontal Cortex (BA9)37.1
- Prostate33.2
- Fallopian Tube32.56
- Colon - Sigmoid31.7
- Esophagus - Gastroesophageal Junction31.58
- Adipose - Visceral (Omentum)31.06
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007200
- GO:0007204
- GO:0043123
- GO:0060326
- GO:1902018
- GO:0005768
- GO:0005886
- GO:0009986
- GO:0030139
- GO:0004930
- GO:0005515
- GO:0035727
- GO:0070915
Related records
Trials (125)
- A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
- A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
- A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
- A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
- A Study of Experimental Medication BMS-986278 Given to Healthy Participants
- A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems
- A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- A Study to Assess the Effect of Food on the Drug Levels of Admilparant
- A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
- A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
- A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
- A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Drugs (5)
- Admilparant
- Amitriptyline
- BMS-986020 Lysophosphatidic acid receptor Edg-2 antagonist
- Fipaxalparant
- Mianserin